Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 28, 2024
Daily News
June 28, 2024
- MHLW to Revise Process to Share Info on Nitrosamine Impurities after Guidance Issued
June 28, 2024
- MHLW Project Team Proposes New Subsidies for Early R&D of Intractable Disease Drugs
June 28, 2024
- MHLW Sets Up Global Strategy HQ to Bolster Innovation Ecosystem
June 28, 2024
- Physician Predicts 30-40% Switch Rate for Chugai’s PNH Drug Piasky
June 28, 2024
- Nxera Snags US$10 Million Milestone from AbbVie in Neurology Collab
June 28, 2024
- FDA Snubs Daiichi Sankyo’s HER3 ADC over Third-Party Manufacturing Issue
June 28, 2024
- Takeda Files Alagille Syndrome Drug Maralixibat in Japan
June 28, 2024
- Ayumi Taps Ex-Ferring Japan CEO as New President
June 28, 2024
- 3 Tips for Establishing Local Connections in Japan
June 28, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…